S
Stephanie Rush
Researcher at University of California, San Francisco
Publications - 23
Citations - 1710
Stephanie Rush is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 10, co-authored 17 publications receiving 1144 citations.
Papers
More filters
Journal ArticleDOI
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Milena A. Gianfrancesco,Kimme L. Hyrich,Sarah Al-Adely,Loreto Carmona,Maria I. Danila,Maria I. Danila,Laure Gossec,Zara Izadi,Lindsay Jacobsohn,Patricia P. Katz,Saskia Lawson-Tovey,Elsa F Mateus,Stephanie Rush,Gabriela Schmajuk,Julia F. Simard,Anja Strangfeld,Laura Trupin,Katherine D Wysham,Suleman Bhana,Wendy Costello,Rebecca Grainger,Jonathan S. Hausmann,Jonathan S. Hausmann,Jean W. Liew,Emily Sirotich,Paul Sufka,Zachary S. Wallace,Jinoos Yazdany,Pedro Machado,Philip Robinson,Philip Robinson +30 more
TL;DR: It is found that glucocorticoid exposure of ≥10 mg/day is associated with a higher odds of hospitalisation and anti-TNF with a decreased odds ofospitalisation in patients with rheumatic disease.
Journal ArticleDOI
Physical Activity Outcomes of CHAMPS II A Physical Activity Promotion Program for Older Adults
Anita L. Stewart,Carol J. Verboncoeur,Barbara Y. McLellan,Dawn Gillis,Stephanie Rush,Kris M. Mills,Abby C. King,Philip L. Ritter,Byron William Brown Jr.,Walter M. Bortz +9 more
TL;DR: The effectiveness of CHAMPS II, an inclusive, choice-based physical activity promotion program to increase lifetime physical activity levels of seniors, is examined to find individually tailored programs to encourage lifestyle changes in seniors may be effective and applicable to health care and community settings.
Journal ArticleDOI
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
Jeffrey A. Sparks,Zachary S. Wallace,Andrea M Seet,Milena A. Gianfrancesco,Zara Izadi,Kimme L. Hyrich,Anja Strangfeld,Laure Gossec,Loreto Carmona,Elsa F Mateus,Saskia Lawson-Tovey,Laura Trupin,Stephanie Rush,Patricia P. Katz,Gabriela Schmajuk,Lindsay Jacobsohn,Leanna Wise,Emily L Gilbert,Alí Duarte-García,Maria O Valenzuela-Almada,Guillermo J. Pons-Estel,Carolina A. Isnardi,Guillermo A. Berbotto,Tiffany Y.T. Hsu,Kristin M. D’Silva,Naomi J Patel,Lianne Kearsley-Fleet,Lianne Kearsley-Fleet,Martin Schäfer,Sandra Lúcia Euzébio Ribeiro,Samar Al Emadi,Liselotte Tidblad,Carlo Alberto Scirè,Bernd Raffeiner,Thierry Thomas,René Marc Flipo,Jérôme Avouac,Raphaèle Seror,Miguel Bernardes,Maria Margarida Cunha,Rebecca Hasseli,Hendrik Schulze-Koops,Ulf Müller-Ladner,Christof Specker,Viviane Angelina de Souza,Licia Maria Henrique da Mota,Ana Paula Monteiro Gomides,Philippe Dieudé,Elena Nikiphorou,Elena Nikiphorou,Vanessa L. Kronzer,Namrata Singh,Manuel F. Ugarte-Gil,Beth I Wallace,Akpabio Akpabio,Ranjeny Thomas,Suleman Bhana,Wendy Costello,Rebecca Grainger,Jonathan S. Hausmann,Jean W. Liew,Emily Sirotich,Paul Sufka,Philip Robinson,Philip Robinson,Pedro Machado,Jinoos Yazdany +66 more
TL;DR: In this article, the authors investigated baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA).
Journal ArticleDOI
Association between etanercept use and employment outcomes among patients with rheumatoid arthritis.
TL;DR: Having been in clinical trials of etanercept clinical trials was associated with higher employment rates in 1999 and a greater number of hours per week of work in that year, suggesting that a randomized trial to establish the relationship between treatment and employment outcomes is now warranted.
Journal Article
The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis.
TL;DR: Poor initial functional status and declining functional status significantly increased mortality risk among persons with RA and to compare the mortality experience of such persons to that of the US population.